"Health is a state of complete physical, mental and social well-being, and not merely the absence of disease or infirmity"  ~World Health Organization, 1948

 

NEW BREAKTHROUGH TECHNOLOGY IMMEDIATELY AVAILABLE FOR LICENSING AND JOINT PRODUCT DEVELOPMENT FOR END-USER-DEFINED TARGETED DIAGNOSTIC, PROGNOSTIC, AND IN VIVO SINGLE-CELL IMAGING APPLICATIONS BASED ON DETECTION OF SPECIFIC RNA AND DNA MOLECULES

Technology describes nano-sensors and methods of their design, engineering, and use for detection and discrimination of nucleic acids with a single nucleotide resolution. Best-performing nano-sensors manifest ~200,000-fold enhancement of nano-device’s sensitivity for detection of RNA molecules. World-wide and regional licensing opportunities. US Patent pending. Technology description is available for confidential review upon request (genlighttec@gmail.com).

Read recent JCI paper on RNA-guided next generation individualized nanomedicine http://www.jci.org/articles/view/69268

GENLIGHT TECHNOLOGIES CORPORATION, INC. (GLTCI) is a privately held corporation with the principal business goal of translation into clinical practice genomic technologies for diagnostic, prognostic, and therapeutic applications enabling clinical implementation of the concept of individualized target-tailored therapies of human disease.

GLTC, Inc. conducts its business through synergistic operations of three divisions: GenLight Consulting, GenLight Diagnostics, and GenLight Therapeutics.

We will provide up-to-date information on ongoing clinical trials to facilitate the assistance in considerations for potential enrollment into clinical trials scientific profiles of which are most likely to provide benefits for individual patients. This service includes an expert advice on meeting the criteria for enrollment and open-enrollment periods.

DURING THE INITIAL CONSULTATION WE WILL CUSTOM-DESIGN THE PORTFOLIO OF CONCIERGE-LEVEL GENOMICS-GUIDED MEDICAL SERVICES THAT SPECIFICALLY ADDRESSES YOUR INDIVIDUAL NEEDS AND BUDGETARY CONSTRAINS.

We provide services assisting our customers to find higher-quality health care providers based on past performance, therapy outcomes, and cost comparisons data.

NEW: We are offering a broad range of proprietary products and services to assist healthy people in understanding the individual's genetic risk of developing common human disorders.

GenLight Technologies Corporation, Inc. (GLTCI)


Our Story

Related Links:

http://iem.ucsd.edu/people/profiles/guennadi-v-glinskii.html

www.facebook.com/genlighttech

https://scholar.google.com/citations?user=zFiGe0EAAAAJ&hl=en&oi=ao

 

Dr. Gennadi Victor Glinsky, MD, Ph.D. is Co-Founder and Director of the Translational & Functional Genomics Program at the Genlight Technology Corporation, La Jolla, CA. Dr. Glinsky holds Consulting Professor appointment at the Stanford University School of Medicine, (Stanford, CA). He is a Member, The Rockefeller University Adjunct Faculty, in the Laboratory of Immune Cell Epigenetics & Signaling (New York, NY). He is an Adjunct Professor at the Department of Surgery, Division of Urology, Albany Medical College, in Albany, NY, Adjunct Professor at the Department of Pathology & Laboratory Medicine, Albany Medical College, in Albany, NY. Since 2011, Dr. Glinsky is Visiting Scholar at the Sanford-Burnham Medical Research Institute, in La Jolla, CA.

Dr. Glinsky is a consultant for the National Institutes of Health and serves on the various Review Panels of the National Institutes of Health and the National Cancer Institute Review Panels. He serves as a reviewer on Review Panels for Israeli Science Foundation, Israel; Canada Foundation for Innovation (CFI), Canada; Health Research Board (HRB), Ireland; Medical Research Council (MRC), United Kingdom; Swiss National Science Foundation, (SNF), Switzerland; Cancer Research UK, London, United Kingdom; Associazione Italiana per la Ricerca sul Cancro (AICR), Italy.                                                                                                                           

Dr. Glinsky serves as a reviewer for numerous journals including The New England Journal of Medicine, Lancet, Nature Medicine, Journal of Clinical Investigation, Cancer Research, American Journal of Pathology, Clinical Cancer Research, Proceedings of the National Academy of Science (PNAS), Oncogene

Dr. Glinsky has over 30 years of experience in conducting cancer research applying his unique set of expertise in clinically relevant animal models of cancer metastasis, molecular biology, molecular imaging, and oncogenomics. Most recently, Dr. Glinsky and colleagues have made groundbreaking observations in the area of genomics of common human diseases highlighting critically important functional role of intergenic non-protein-coding regions in pathogenesis of human disorders. Laboratory experiments and computational analyses conducted in Dr. Glinsky?s laboratory facilitated isolation, sequencing, and functional characterization of small non-coding trans-regulatory RNAs (transRNAs) containing intergenic disease-associated SNPs (snpRNAs) and inducing allele-specific clinically-relevant phenotypic changes in human cells. These observations challenge dominant position of the protein-centric experimental dogma in genetic and molecular analysis of physiology and pathology of H. sapiens. During his tenure at the Sidney Kimmel Cancer Center (1998-2005), Dr. Glinsky’s laboratory has made a major contributor to the invention, development, and practical implementation of the concept and principles of the “signature approach” to genome-wide microarray gene expression analysis (citation range of key papers 236-650). His recent work in the mouse/human cross-species translational genomics field has made a major impact on discovery of the genetic link between the “stemness” phenotype and therapy-resistance clinical behavior of human cancer. He invented the gene expression-based cancer therapy outcome predictor (CTOP) algorithm and carry-out the retrospective clinical validation of the multi-signature CTOP algorithm for four distinct types of epithelial tumors, including breast, prostate, lung, and ovarian cancers. Dr. Glinsky’s lab was at the origin of discoveries of the links between metastatic behavior and apoptosis-resistance phenotypes, telomerase- and telomere-length-dependent mechanisms of resistance to apoptosis, isolation and genomic analysis of blood-borne human prostate carcinoma metastasis precursor cells, and mechanism- and structure-guided anti-metastatic drug design and pre-clinical evaluation (citation range of key papers (88-340). Dr. Glinsky is one of the originators of the concept of anti-adhesion cancer therapy and is a leading specialist in the field of anti-adhesion therapy of metastatic disease. During his tenure at the Academy of Science of Ukraine (1983-1990) and career transition to the United States (1990-1998), Dr. Glinsky’s lab has made a major contributor to the discovery and preclinical development of low molecular weight family of therapeutic compounds named antimetastatic synthetic glycoamines (citation range of key papers 56-140).

Dr. Glinsky earned a doctor of medicine in internal medicine.  He later received his doctorate in experimental oncology from the Institute of Oncology Problems Academy of Sciences of Ukraine in Kiev, Ukraine. He completed his post-doctoral training and early-stage scientific career as Senior Scientist, Group Leader, and Program Director in the Institute of Oncology Problems Academy of Sciences of Ukraine in Kiev, Ukraine (1982-1991).